Induced Pluripotent Stem Cells (iPSCs)

Q: What iPSC services does Cyagen provide?

Cyagen provides end-to-end iPSC solutions covering somatic cell reprogramming, gene editing, directed differentiation, disease modeling, drug evaluation, and downstream in vivo validation. This integrated workflow helps reduce project handoffs and supports the development of disease-relevant models from initial sample to functional study.

Q: What types of starting materials can be used for iPSC reprogramming?

Cyagen supports iPSC generation from multiple types of human somatic cells. In addition to blood-derived cells such as PBMCs, demonstrated starting materials include adult fibroblasts, chorionic villus cells, and amniotic fluid-derived cells. Reprogramming strategies can be optimized according to sample type, cell condition, and available sample quantity.

Q: What reprogramming method is used to generate iPSCs?

Cyagen uses a non-integrating episomal plasmid-based reprogramming method. This approach avoids permanent integration of reprogramming vectors into the host genome, making the resulting iPSCs suitable for downstream disease modeling, gene editing, differentiation, and drug discovery applications.

Q: How long does iPSC reprogramming take?

Depending on the cell type and project requirements, timelines may vary, with validated Passage 10 (P10) iPSC clones delivered in as fast as 12 weeks. The standard reprogramming package includes clone generation and comprehensive quality control, with additional characterization assays available depending on project requirements.

Q: How are iPSC clones characterized and quality controlled?

iPSC quality control can include cell morphology assessment, STR profiling, karyotyping, immunofluorescence staining of pluripotency markers such as OCT4 and NANOG, flow cytometry for SSEA4 and TRA-1-81, sterility testing, and mycoplasma testing. Three-germ-layer differentiation and teratoma formation assays are also available as optional assessments.

Q: Can Cyagen work with challenging or limited starting samples?

Yes. Cyagen specializes in iPSC reprogramming from challenging or limited starting samples, including low-cell-number and poor-quality PBMC samples. With extensive experience handling difficult samples, our team can tailor the reprogramming strategy to individual sample conditions. We also offer a free sample feasibility evaluation to assess whether your starting material is suitable for reprogramming before the project begins.

Q: What types of gene editing can be performed in iPSCs?

Cyagen supports gene knockout, gene knock-in, point mutation, knockdown, and overexpression strategies in iPSCs. The workflow combines optimized editing design, RNP delivery, electroporation, monoclonal screening, sequencing, and cell-level validation to generate genetically defined iPSC models for disease research and drug development.

Q: What differentiated cell types can be generated from iPSCs?

Cyagen provides directed differentiation into multiple disease-relevant cell types, including neural progenitor cells, cortical neurons, dopaminergic neurons, motor neurons, retinal pigment epithelial cells, and hematopoietic progenitor cells. Additional capabilities include specialized neural and organoid models for disease modeling and drug discovery.

Q: Can gene-edited iPSCs be differentiated into disease-relevant cell types?

Yes. Gene editing and directed differentiation can be integrated within the same project. This enables researchers to introduce disease-associated mutations or other genetic modifications into iPSCs and subsequently differentiate them into relevant cell types for phenotype characterization, mechanistic studies, and therapeutic evaluation.

Q: Can Cyagen's iPSC models be used for drug screening and efficacy studies?

Yes. iPSC-derived disease models can be characterized using molecular markers, morphology, protein expression, functional assays, and electrophysiological measurements. The platform can also support therapeutic evaluation, including ASO activity studies and drug screening. For example, Cyagen's iPSC-derived cortical and dopaminergic neurons have demonstrated functional maturation and dose-dependent target gene knockdown following ASO treatment.

Cyagen’s iPSC services provide high-efficiency reprogramming, precise gene editing, and optimized differentiation for disease modeling, drug discovery, and regenerative medicine.

End-to-End iPSC Solutions

Integrated reprogramming, gene editing, directed differentiation, drug screening, and in vivo validation.

Advanced Differentiation

Generation of complex cell types and organoids for disease modeling and drug discovery.

Reliable Reprogramming

Up to 99% success rate, with one complimentary repeat for unsuccessful initial projects.

Overview

Workflow

FAQs

Overview

Comprehensive iPSC Solutions

Cyagen provides an integrated iPSC platform spanning reprogramming, gene editing, directed differentiation, drug screening, and in vivo validation. Backed by nearly 20 years of stem cell expertise, our standardized workflows help reduce project handoffs and accelerate the development of reliable disease models.

● High-Efficiency Reprogramming: Non-integrating reprogramming with success rates of up to 99%. Validated P10 clones can be delivered in as fast as 12 weeks.
● Precision Gene Editing: Knockout, knock-in, and point mutation services with KO efficiencies of up to 90% and optimized HDR efficiencies of up to 50%.
● Advanced Differentiation: Generation of disease-relevant cells and organoids, including cortical, dopaminergic, and motor neurons, astrocytes, microglia, blood cells, liver organoids, and brain organoids.
● Rigorous Quality Control: Comprehensive validation of pluripotency, karyotype, cell identity, functionality, and reproducibility.

Supported by standardized project management and Ph.D.-level technical expertise, Cyagen delivers dependable iPSC models for disease research and drug development.

Explore Ready-to-Use IPSC Models

Explore Cyagen's growing library of off-the-shelf iPSC models—including knockout, knock-in, and disease-relevant point mutation cell lines—supporting research in neurology, ophthalmology, immunology, and beyond. Search by gene, modification type, disease area, or cell format to quickly identify the right model and accelerate disease modeling, target validation, and drug discovery.

Workflow and Delivery

Cyagen provides a streamlined, high-efficiency workflow for iPSC development, from reprogramming and gene editing to directed differentiation. Our optimized processes ensure high success rates, rigorous quality control, and fast turnaround times to support your research needs.

iPSC Reprogramming

Cyagen utilizes advanced somatic cell reprogramming technology to reprogram somatic cells collected from blood samples, generating high-quality human induced pluripotent stem cells (hiPSCs) with a success rate of up to 99%. We employ a robust, non-integrating episomal plasmid reprogramming method, ensuring downstream experiments remain completely unaffected. Furthermore, our standardized operating procedures are compatible with various culture systems, enabling the large-scale production of high-purity cells.

Key Advantages of Our iPSC Reprograming Workflow

Extensive Stem Cell Expertise

Nearly 20 years of stem cell research experience, supported by established workflows and a comprehensive research-grade stem cell bank.

Robust, Non-Integrating Reprogramming

Standardized, non-integrating reprogramming protocols and optimized culture conditions support reliable generation of high-quality iPSC clones.

Fast & Reliable Delivery

Receive Passage 10 (P10) iPSC clones in as fast as 12 weeks, backed by an on-time delivery rate of ≥99%.

Seamless Downstream Integration

Extend your project from iPSC reprogramming to gene editing, differentiation, characterization, and downstream in vitro or in vivo studies through one coordinated workflow.

Service Process

iPSC Reprogramming Service Content

iPSC Gene Editing

Cyagen features a well-established and robust gene editing platform backed by experience from over 10,000 gene editing projects and a proven track record of successful iPSC applications. Supported by the Rare Disease Data Center RNA splicing model for efficient screening of WB-validated protein-deficient clones. Leveraging the Cell iGeneEditor™ System, we routinely execute diverse strategies including gene knockouts (KO), gene knock-ins (KI), point mutations (PM), and stable cell line generation, achieving editing efficiencies of up to 90-95%. Our services are highly applicable for disease mechanism research, drug screening platform development, and cell therapy applications, supporting disease modeling, drug discovery, and translational research.

Key Advantages of Our iPSC Reprograming Workflow

High-Efficiency Editing

Proprietary α-donor vector HDR system achieves up to 87% HDR efficiency and supports homozygous clone generation. KO efficiency reaches up to 95%.

Robust Quality Control

Optimized RNP delivery, premium culture media, and standardized workflows support high cell viability, editing accuracy, and consistent iPSC quality.

Rapid & Reliable Turnaround

Custom iPSC gene editing projects delivered in as fast as 8 weeks, with an on-time delivery rate of ≥99%.

AI-Assisted Design & Expert Support

Cell iGeneEditor™ supports multiple editing strategies, while AI-based tools assist clone screening. Ph.D.-level scientists provide technical support throughout the project.

iPSC Gene Editing Service Workflow

Gene lethality/homology analysis
AI-assisted design strategy
Cell iGeneEditor™ System

RNP delivery
Optimized α-donor

High-efficiency electroporation system
Polyclonal analysis technology

Optimized monoclonal generation process
Monoclonal screening and analysis technology

Sanger sequencing and IF
Sterility & Mycoplasma testing
qPCR/WB/FC/Karyotyping/Off-target (Optional)

iPSC Gene Editing Case Studies

iPSC Directed Differentiation

Directed differentiation involves guiding iPSCs into target somatic cell types—such as neurons, cardiomyocytes, and hepatocytes—under specific experimental conditions and cell culture systems. Cyagen provides diverse disease modeling and drug screening platforms, offering premium, highly customizable services for researchers.

iPSC Differentiated Cells

iPSC Directed Differentiation Case Studies

iPSC Disease Modeling & Drug Evaluation

Cyagen provides iPSC-derived disease models that recapitulate disease-relevant genetic backgrounds and cellular phenotypes for translational research. Using differentiated cell types such as cortical and dopaminergic neurons, we support comprehensive model characterization through morphology, disease-related marker analysis, functional assays, and electrophysiological evaluation. These validated models can be further applied to therapeutic efficacy studies, including ASO activity evaluation, drug screening, and disease mechanism research.

Key Advantages of Our iPSC Reprograming Workflow

Disease-Relevant Models

Genetically defined iPSC-derived models for studying disease-associated phenotypes and mechanisms.

Functional Characterization

Integrated evaluation using molecular markers, morphology, protein expression, and electrophysiological assays.

Therapeutic Evaluation

Flexible assay platforms for assessing ASOs and other therapeutic candidates in disease-relevant cellular systems.

Ph.D.-Level Scientific Support

Dedicated Ph.D. scientists provide guidance on model selection, assay design, data interpretation, and study planning.

Case Studies

FAQs

Frequently Asked Questions (FAQs)

What iPSC services does Cyagen provide?

What types of starting materials can be used for iPSC reprogramming?

What reprogramming method is used to generate iPSCs?

How long does iPSC reprogramming take?

How are iPSC clones characterized and quality controlled?

Can Cyagen work with challenging or limited starting samples?

What types of gene editing can be performed in iPSCs?

What differentiated cell types can be generated from iPSCs?

Can gene-edited iPSCs be differentiated into disease-relevant cell types?

Can Cyagen's iPSC models be used for drug screening and efficacy studies?

Are ready-to-use iPSC models and differentiated cells available?

Why use an integrated iPSC platform instead of separate service providers?

Customer Publications Featuring Cyagen iPSC Solutions

Explore peer-reviewed studies published by researchers using Cyagen’s iPSC-related services and ready-to-use iPSC lines. These studies highlight how our integrated capabilities in iPSC reprogramming, gene editing, cell line development, disease modeling, and directed differentiation help researchers establish reliable human cellular models, investigate disease mechanisms, validate therapeutic targets, evaluate drug candidates, and support translational research across multiple disease areas.

Journal	Papers	Our Product	Application	IF
Advanced Science	PCSK9 Loss-of-Function Disrupts Cellular Microfilament Network via LIN28A/HES5/JMY Axis in Neural Tube Defects	PCSK9 knockout, PCSK9 R46L mutation, and VANGL2 knockout	Neural tube defects (NTDs)	Q1 14.1
Nature Communications	Altered chromatin topologies caused by balanced chromosomal translocation lead to central iris hypoplasia	Ehancer knockout	Central iris hypoplasia	Q1 15.7
Cell and Bioscience	Generation and transcriptomic characterization of MlR137 knockout miniaturepig model for neurodevelopmental disorders	MIR137 knockout	Neurodevelopmental disorders (NDDs)	Q1 6.2

FULL CITATION LIBRARY

From Published Research to Broader iPSC Applications

Explore the full collection of peer-reviewed customer publications featuring Cyagen iPSC lines and iPSC-related services. Discover how researchers use these solutions in gene editing, disease modeling, target validation, drug discovery, and translational research across diverse therapeutic areas.

Explore All Publications →

Request a Custom Cell Line Consultation

Tell us about your cell line project needs. Our specialists are ready to support your research with tailored solutions.

Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:

Yes, I want to receive updates on products, services, and events from Cyagen.

You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.

By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.